Used in cancer immunotherapy research, particularly targeting tumors that overexpress MUC1, a glycoprotein commonly found in epithelial cancers such as breast, ovarian, and pancreatic cancers. It serves as a reference standard in the development and validation of MUC1-targeted therapeutic antibodies and diagnostic assays. Gatipotuzumab helps evaluate binding affinity, specificity, and functional activity of new anti-MUC1 candidates in preclinical studies. It is also employed in flow cytometry, immunohistochemistry, and ELISA to detect MUC1 expression in tumor samples, supporting biomarker research and patient stratification in clinical trials.